Biomarker ID | 1508 |
PMID | 25139197 |
Year | 2014 |
Biomarker | Prostate Health Index (PHI) |
Biomarker Basis | Concentration Based (pg/mL) |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Upregulated in patients with Grade pT3 or GS ≥ 7 |
Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR= 0.02 (0.02–0.03), p < 0.001, 0.74 (0.69–0.79) |
Effect on Pathways | NA |
Experiment | Both adverse pathologic characteristics (pT3 disease and pathologic Gleason score I7) |
Type of Biomarker | Prognostic |
Cohort | The study cohort consisted of 489 patients with biopsy-proven clinically localised PCa who underwent either open or robot-assisted laparoscopic RP. 134 had stage pT3 and 336 had Gleason Score ≥ 7 |
Senstivity | NA |
Specificity | NA |
AUC | 0.69 (95% CI: 0.64–0.74) |
Accuracy | NA |
Level Of Significance | p < 0.001 |
Method Used | UniCel DxI800 Immunoassay System analyser |
Clinical | No |
Remarks | PHI = [(p2PSA / fPSA) / √tPSA] |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |